First, CCR2-KO or Merestinib treatment alone reduced the growth and survival of mammary carcinomas and inhibited M2 macrophage recruitment, indicating disruptions to CCL2 and HGF signaling with inhibition of CCR2 or MET. Here, CCL2 is linked to breast carcinoma.